Fig. 6

CD44v3 mimetic peptide 4 blocks MDA-MB-231 tumor growth and metastasis. Schematic representation of the experimental setup for MDA-MB-231 tumor growth assessment in SCID mice (A). Body weight (B) and tumor volume (C) were measured following CD44v3 mimetic peptide administration (10 mice per group). Schematic representation of the experimental setup for MDA-MB-231 metastasis assessment in SCID mice (D). Percentage of metastasis-positive lungs, brains and livers (E) after scramble peptide or CD44v3 mimetic peptide 4 treatment (3 mice/group) or (F) after TrkA-H112 mutant treatment (6 mice) compared with HA-TrkA cells (5 mice). ** p < 0.01; ns, nonsignificant. T test